Humira Pen 40 mg/0.8 mL - Crohn's Disease/Ulcerative Colitis Starter Pack
RxNorm 825170
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 825170 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: Humira Pen 40 mg/0.8 mL - Crohn's Disease/Ulcerative Colitis Starter Pack.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SYPrescribable
Synonym (SY):
Humira Pen 40 mg/0.8 mL - Crohn's Disease Starter Pack
(Atom ID: 6411575)
PSNPrescribable
Prescribable Name (PSN):
Humira Pen 40 mg/0.8 mL - Crohn's Disease/Ulcerative Colitis Starter Pack
(Atom ID: 7246550)
SYPrescribable
Synonym (SY):
Humira Pen 40 mg/0.8 mL - Crohn's Disease/Ulcerative Colitis Starter Pack
(Atom ID: 6811880)
BPCKPrescribable
Brand Name Pack (BPCK):
{6 (0.8 mL adalimumab 50 mg/ML Auto-Injector [Humira]) } Pack [Humira Pen - Crohn's Disease Starter Pack]
(Atom ID: 7250430)
Patient Education
Adalimumab Injection
Adalimumab injection is used alone or with other medications to relieve the symptoms of certain autoimmune disorders (conditions in which the immune system attacks healthy parts of the body and causes pain, swelling, and damage) including the following: rheumatoid arthritis (a condition in which the body attacks its own joints, causing pain, swelling, and loss of function) in adults, juvenile idiopathic arthritis (JIA; a condition that affects children in which the body attacks its own joints, causing pain, swelling, loss of function, and delays in growth and development) in children 2 years of age and older, Crohn's disease (a condition in which the body attacks the lining of the digestive tract, causing pain, diarrhea, weight loss, and fever) that has not improved when treated with other medications in adults and children 6 years of age and older, ulcerative colitis (a condition which causes swelling and sores in the lining of the colon [large intestine] and rectum) when other medications and treatments did not help or could not be tolerated in adults and children 5 years of age and older, ankylosing spondylitis (a condition in which the body attacks the joints of the spine and other areas causing pain and joint damage) in adults, psoriatic arthritis (a condition that causes joint pain and swelling and scales on the skin) in adults, hidradenitis suppurativa (a skin disease that causes pimple-like bumps in the armpits, groin, and anal area) in adults and children 12 years of age and older, uveitis (swelling and inflammation of different areas of the eye) in adults and children 2 years of age and older, chronic plaque psoriasis (a skin disease in which red, scaly patches form on some areas of the body) in adults. Adalimumab injection is in a class of medications called tumor necrosis factor (TNF) inhibitors. It works by blocking the action of TNF, a substance in the body that causes inflammation.
[Learn More]
* Please review the disclaimer below.
